Gdansk

• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia Ended recruitment
  2023-509170-33-00 5 2021-11-23 Classic Congenital Adrenal Hyperplasia (CAH)
• A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Len … Ended recruitment
  2023-505807-21-00 5 2021-11-16 Relapsed/refractory follicular lymphoma
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended recruitment
  2023-506518-33-00 5 2021-11-10 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506257-37-00 5 2021-10-29 Active Psoriatic Arthritis
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati … Ended recruitment
  2023-507342-84-00 5 2021-10-26 Bladder Cancer
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended recruitment
  2023-506177-35-00 11 2021-10-23 Ovarian, fallopian tube, or primary peritoneal carcinoma.
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended recruitment
  2022-503105-38-00 5 2021-10-22 MET-driven, unresectable and locally advanced or metastatic Papillary
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506256-25-00 5 2021-10-20 Active Psoriatic Arthritis
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects … Ended recruitment
  2023-506094-35-00 3 2021-09-17 Newly diagnosed aggressive B-cell lymphoma (a-BCL)
• Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children with Neurofibro … Ended recruitment
  2024-517216-29-00 3 2021-08-06 Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len … Ended recruitment
  2023-505850-16-00 5 2021-08-05 Multiple Myeloma
• Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended recruitment
  2023-504447-14-00 10 2021-07-29 Treatment of pediatric subjects with moderate to severe chronic plaque
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended recruitment
  2022-502856-29-00 7 2021-07-27 Advanced Solid Tumors
• Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab Ended recruitment
  2024-516543-26-00 5 2021-07-23 Type 1 Diabetes Mellitus
• A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS) Ended recruitment
  2023-505089-27-00 5 2021-07-01 Atypical Hemolytic Uremic Syndrome (aHUS)
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas … Ended recruitment
  2024-517253-27-00 5 2021-07-01 Acute lymphoblastic leukemia
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap … Ended recruitment
  2023-506311-18-00 1 2021-06-29 Advanced or metastatic solid tumors with KRAS G12C mutation
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
• Long-term safety of apraglutide in short bowel syndrome Ended recruitment
  2023-510389-28-00 5 2021-06-14 short bowel syndrome
• A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr … Ended recruitment
  2024-510588-53-00 11 2021-06-10 Treatment of patients with HER2-positive breast cancer with or without
• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi … Ended recruitment
  2023-509635-89-00 9 2021-06-01 DIPSS-Intermediate or High Risk Myelofibrosis

Showing 529–552 of 854 trials